Min Wang
President at Ensoma, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Edgardo Rodriguez-Lebron | M | - |
Lacerta Therapeutics, Inc.
 Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | 7 years |
| Jacqualyn Fouse | M | 62 | 7 years | |
| Andrew Schiff | M | 58 | 4 years | |
| May Kin Ho | M | 71 | 9 years | |
| Christine Siu | F | 47 | 4 years | |
| Chandra Paul Leo | M | 53 | 4 years | |
| David Scadden | M | 71 | 7 years | |
| Kush Parmar | M | 42 |
Ensoma, Inc.
 Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
| Kaye Foster-Cheek | F | 64 | 10 years | |
| Albert Seymour | M | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
| Kouki Harasaki | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
| Ellen Lopresti | F | - | 7 years | |
| Amy Griffin | F | - |
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | - |
| Joseph Zenkus | M | - |
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | - |
| Mark Chin | M | 42 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
| Clive Patience | M | 60 | 7 years | |
| Michael Rapé | M | - | 4 years | |
| Paula Soteropoulos | F | 56 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | 4 years |
| Marc Wolff | M | - |
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | 3 years |
| Jackson Streeter | M | - |
Lacerta Therapeutics, Inc.
Lacerta Therapeutics, Inc. BiotechnologyHealth Technology Lacerta Therapeutics, Inc. operates as a a clinical stage gene therapy company. The firm engages in development, production, and application of AAV vectors. The company was founded by Nicholas Muzyczka, Barry Byrne, Arun Srivastava, Coy Heldermon, Sergei Zolothukin, Kenneth Warrington, Ronald Mandel, Toadd E. Golde and Edgardo Rodriguez in 2017 and is headquartered in Alachua, FL. | - |
| Jim Burns | M | 46 | 8 years | |
| Nihal Sinha | M | - |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Kevin Starr | M | 61 | 7 years | |
| Marc Tessier-Lavigne | M | 64 | 5 years | |
| John Maraganore | M | 60 | 13 years | |
| Perry Karsen | M | 69 | 5 years | |
| Holly Manning | F | - | 6 years | |
| Ian Clark | M | 62 | 6 years | |
| Darrin Miles | M | - | 6 years | |
| Glenn Goddard | M | 53 | 6 years | |
| Lewis Cantley | M | 75 | 10 years | |
| Paul Clancy | M | 62 | 10 years | |
| Robert Nelsen | M | 60 | 10 years | |
| Megan E. Pace | F | 51 | - | |
| Thomas-Christian Mix | M | 57 | 1 years | |
| Renee T. Leck | F | - | 3 years | |
| Jacqueline Cinicola | F | - | 7 years | |
| Eyal Attar | M | 53 | 5 years | |
| Owen Wallace | M | 55 | 3 years | |
| Kevin Marks | M | - | 2 years | |
| Richa Poddar | F | - | 6 years | |
| Samuel Agresta | M | 51 | 7 years | |
| Ann J. Barbier | M | 59 | 2 years | |
| Carman Alenson | F | 58 | 5 years | |
| Christopher Bowden | M | 63 | 7 years | |
| Melissa McLaughlin | F | - | 7 years | |
| Robert Sheroff | M | 69 | 2 years | |
| Camille Henderson | M | - | 4 years | |
| Scott Biller | M | 68 | 9 years | |
| Marion Dorsch | M | 59 | 4 years | |
| Robert J. DeVita | M | - | - | |
| John Evans | M | 46 | 8 years | |
| Steven Hoerter | M | 53 | 3 years | |
| Andrew Hirsch | M | 53 | 4 years | |
| Ajim Tamboli | M | 47 | 3 years | |
| John Duncan Higgons | M | 69 | 7 years | |
| Douglas Cole | M | 63 | 10 years | |
| Meredith Goldwasser | M | 52 | 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 58 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Min Wang
- Personal Network
